Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
8 studies found for:    panobinostat, multiple myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak
2 Available An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
3 Recruiting Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
4 Recruiting Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Condition: Relapse/Refractory Multiple Myeloma
Interventions: Drug: LBH589 (panobinostat);   Drug: bortezomib;   Drug: dexamethasone
5 Recruiting Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: panobinostat capsules;   Drug: bortezomib injection;   Drug: dexamethasone tablets
6 Recruiting Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Busulfan;   Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Dexamethasone acetate;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Procedure: Stem Cell Transplant
7 Not yet recruiting Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
Condition: Relapse and / or Refractory Myeloma
Intervention: Drug: Daratumumab, thalidomide and dexamethasone
8 Recruiting Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Lymphoma, Non-Hodgkin's;   Leukemia, T-Cell;   Leukemia, B-Cell
Interventions: Drug: Dexamethasone;   Drug: Panobinostat;   Drug: Liposomal vincristine;   Drug: Mitoxantrone;   Drug: Peg-asparaginase;   Drug: Bortezomib;   Drug: Intrathecal Triples;   Drug: High-dose methotrexate;   Drug: 6-Mercaptopurine;   Drug: High-dose cytarabine;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Clofarabine

Study has passed its completion date and status has not been verified in more than two years.